News | August 16, 2023
Exor to buy 15% shareholding in Philips
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
CiplaMed 2.0 leverages advanced analytics and automation
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Subscribe To Our Newsletter & Stay Updated
